BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 14655506)

  • 1. [Selective aldosterone blocking in heart failure. Eplerenone reduces the risk after infarction].
    MMW Fortschr Med; 2003 Oct; 145(44):42-3. PubMed ID: 14655506
    [No Abstract]   [Full Text] [Related]  

  • 2. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of heart failure after myocardial infarction. With eplerenone a new course].
    MMW Fortschr Med; 2004 Oct; 146(43):58-9. PubMed ID: 15559524
    [No Abstract]   [Full Text] [Related]  

  • 4. [More benefit in hypertension and high-grade reduction of the pump performance. Earlier beginning of therapy maximizes the benefit].
    MMW Fortschr Med; 2004 Oct; 146(43):59. PubMed ID: 15559525
    [No Abstract]   [Full Text] [Related]  

  • 5. Eplerenone reduces morbidity and mortality after acute MI.
    Cardiovasc J S Afr; 2006; 17(5):280. PubMed ID: 17117244
    [No Abstract]   [Full Text] [Related]  

  • 6. New therapy update. Inspra (eplerenone tablets).
    Kloner RA
    Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
    [No Abstract]   [Full Text] [Related]  

  • 7. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 8. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aldosterone and its antagonists in heart failure].
    Lopes ME; Le Corvoisier P; Tabet JY; Su JB; Badoual T; Cachin JC; Merlet P; Castaigne A; Hittinger L
    Presse Med; 2003 Jan; 32(2):79-87. PubMed ID: 12653034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 14. Pfizer launches Inspra for heart failure.
    Cardiovasc J S Afr; 2006; 17(4):220. PubMed ID: 17001435
    [No Abstract]   [Full Text] [Related]  

  • 15. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: eplerenone: an underused medication?
    Abuannadi M; O'Keefe JH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.